Article preview reprinted from IN VIVO - March, 2009
For most diagnostics companies, the prospect of premium pricing has been an elusive dream. The health care landscape is peppered with expensive novel drugs priced to underscore their clinical impact on patient care.
How to Earn the Economic Payback Diagnostics Companies Deserve
Article preview reprinted from IN VIVO - March, 2009
A similar strategy for pricing novel diagnostics with significant clinical impact makes sense, especially since many of them are driving the decisions to deploy novel drugs in the first place. Now, strong system economics arguments are becoming more mainstream and payors are beginning to reward companies with reimbursement of their premium priced tests, based upon rigorous clinical arguments supporting the diagnostics' benefits to clinical decision-making and compelling economic arguments customized to each major payer.
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed. Subscribe to IN VIVO.
Companies mentioned in this article:
Asterand PLC
Clinical Data Inc.
CombiMatrix Corp.
CombiMatrix Molecular Diagnostics Inc.
DiagnoCure Inc.
Exact Sciences Corp.
Genomic Health Inc.
Genzyme Corp.
Genzyme General
Genzyme Genetics
Hologic Inc.
Johnson & Johnson
Veridex LLC
Immunicon Corp.
Monogram Biosciences Inc.
Myriad Genetics Inc.
Response Genetics Inc.
Roche
Genentech Inc.
Rosetta Genomics Ltd.
XDx Inc.
IN VIVO delivers:
- Revealing, in-depth coverage of your competitors' strategies
- Incisive projections of future industry trends and their implications for your business
- Expert analysis of key industry developments
- Exclusive interviews with top industry executives and analysts
- In-depth examination of dealmaking, marketing, R&D, regulatory, and finance strategies -- those that were successful and those that missed the mark
- Subscribe to IN VIVO today!
